🇺🇸 Dopamine Agonists in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Hallucination — 2 reports (18.18%)
  2. Agitation — 1 report (9.09%)
  3. Anxiety — 1 report (9.09%)
  4. Balance Disorder — 1 report (9.09%)
  5. Bradyphrenia — 1 report (9.09%)
  6. Cholecystitis — 1 report (9.09%)
  7. Cognitive Disorder — 1 report (9.09%)
  8. Confusional State — 1 report (9.09%)
  9. Constipation — 1 report (9.09%)
  10. Covid-19 — 1 report (9.09%)

Source database →

Other Neurology approved in United States

Frequently asked questions

Is Dopamine Agonists approved in United States?

Dopamine Agonists does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Dopamine Agonists in United States?

Leiden University Medical Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.